Amidst the ongoing challenges posed by the COVID-19 pandemic and the potential rise of new variants, it becomes increasingly evident that robust screening measures are pivotal in not only managing the current crisis but also in fortifying global readiness for potential future pandemics.

The current screening methods for detecting asymptomatic infections have been widely criticized for being excessively expensive, time-consuming, invasive, and leading to unnecessary delays. Furthermore, rapid tests have been deemed ineffective at identifying asymptomatic infections. Another drawback is the limited shelf life of current screening methods, which necessitates their disposal - an expensive proposition for any government or institution.

SpotLight-19© is designed to overcome the limitations of other test methods. Unlike existing methods, SpotLight-19© not only mitigates the need for costly and time-consuming processes but also eliminates the invasiveness and delays associated with traditional screening. One of the key features of SpotLight-19© is its unique ability to recalibrate and effectively identify new variants and viruses. This is a significant advancement over current screening methods, as it ensures that the technology remains effective in the face of evolving pathogens.